Intermittent screening and treatment with dihydroartemisinin-piperaquine and intermittent preventive therapy with sulfadoxine-pyrimethamine have similar effects on malaria antibody in pregnant Malawian women

[1]  D. Narum,et al.  Intermittent screening and treatment with dihydroartemisinin-piperaquine and intermittent preventive therapy with sulfadoxine-pyrimethamine have similar effects on malaria antibody in pregnant Malawian women , 2019, Scientific Reports.

[2]  S. Issifou,et al.  Persistent Plasmodium falciparum Infection in Women With an Intent to Become Pregnant as a Risk Factor for Pregnancy-associated Malaria , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  J. Simpson,et al.  Host immunity to Plasmodium falciparum and the assessment of emerging artemisinin resistance in a multinational cohort , 2017, Proceedings of the National Academy of Sciences.

[4]  J. Beeson,et al.  Functional Antibodies and Protection against Blood-stage Malaria. , 2016, Trends in parasitology.

[5]  Steve M. Taylor,et al.  Scheduled Intermittent Screening with Rapid Diagnostic Tests and Treatment with Dihydroartemisinin-Piperaquine versus Intermittent Preventive Therapy with Sulfadoxine-Pyrimethamine for Malaria in Pregnancy in Malawi: An Open-Label Randomized Controlled Trial , 2016, PLoS medicine.

[6]  N. Lazar,et al.  The ASA Statement on p-Values: Context, Process, and Purpose , 2016 .

[7]  A. Wey,et al.  Influence of Intermittent Preventive Treatment on Antibodies to VAR2CSA in Pregnant Cameroonian Women. , 2016, The American journal of tropical medicine and hygiene.

[8]  Steve M. Taylor,et al.  The A581G Mutation in the Gene Encoding Plasmodium falciparum Dihydropteroate Synthetase Reduces the Effectiveness of Sulfadoxine-Pyrimethamine Preventive Therapy in Malawian Pregnant Women. , 2015, The Journal of infectious diseases.

[9]  P. Siba,et al.  Malaria preventive therapy in pregnancy and its potential impact on immunity to malaria in an area of declining transmission , 2015, Malaria Journal.

[10]  K. Maleta,et al.  The impact of lipid-based nutrient supplementation on anti-malarial antibodies in pregnant women in a randomized controlled trial , 2015, Malaria Journal.

[11]  P. Deloron,et al.  Protective Antibodies against Placental Malaria and Poor Outcomes during Pregnancy, Benin , 2015, Emerging infectious diseases.

[12]  M. Molyneux,et al.  Decreasing malaria prevalence and its potential consequences for immunity in pregnant women. , 2014, The Journal of infectious diseases.

[13]  D. Garboczi,et al.  Antigen Reversal Identifies Targets of Opsonizing IgGs against Pregnancy-Associated Malaria , 2014, Infection and Immunity.

[14]  R. Morrison,et al.  Intermittent Preventive Treatment in Pregnant Women Is Associated with Increased Risk of Severe Malaria in Their Offspring , 2013, PloS one.

[15]  J. Simpson,et al.  New Insights into Acquisition, Boosting, and Longevity of Immunity to Malaria in Pregnant Women , 2012, The Journal of infectious diseases.

[16]  Kevin Marsh,et al.  Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity. , 2012, The Journal of clinical investigation.

[17]  Joseph D. Smith,et al.  High Avidity Antibodies to Full-Length VAR2CSA Correlate with Absence of Placental Malaria , 2012, PloS one.

[18]  Q. Bassat,et al.  Transcription of var genes other than var2csa in Plasmodium falciparum parasites infecting Mozambican pregnant women. , 2011, The Journal of infectious diseases.

[19]  Joseph D. Smith,et al.  Induction of strain-transcendent antibodies to placental-type isolates with VAR2CSA DBL3 or DBL5 recombinant proteins , 2011, Malaria Journal.

[20]  K. Maleta,et al.  Antibodies to chondroitin sulfate A-binding infected erythrocytes: dynamics and protection during pregnancy in women receiving intermittent preventive treatment. , 2010, The Journal of infectious diseases.

[21]  K. Marsh,et al.  Intermittent Preventive Sulfadoxine-Pyrimethamine Treatment of Primigravidae Reduces Levels of Plasma Immunoglobulin G, Which Protects against Pregnancy-Associated Plasmodium falciparum Malaria , 2004, Infection and Immunity.

[22]  Kevin Marsh,et al.  Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria , 2004, The Lancet.

[23]  Thomas Lavstsen,et al.  Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A‐adhering Plasmodium falciparum involved in pregnancy‐associated malaria , 2003, Molecular microbiology.

[24]  M. Valiyaveettil,et al.  Gravidity-Dependent Production of Antibodies That Inhibit Binding of Plasmodium falciparum-Infected Erythrocytes to Placental Chondroitin Sulfate Proteoglycan during Pregnancy , 2001, Infection and Immunity.

[25]  R. Leke,et al.  Acquisition and decay of antibodies to pregnancy-associated variant antigens on the surface of Plasmodium falciparum-infected erythrocytes that protect against placental parasitemia. , 2001, The Journal of infectious diseases.

[26]  François Nosten,et al.  Maternal antibodies block malaria , 1998, Nature.

[27]  T. Perneger.  What's wrong with Bonferroni adjustments , 1998, BMJ.

[28]  S. Rogerson,et al.  A Robust Phagocytosis Assay to Evaluate the Opsonic Activity of Antibodies against Plasmodium falciparum-Infected Erythrocytes. , 2015, Methods in molecular biology.

[29]  S. Rogerson,et al.  Evaluating IgG Antibody to Variant Surface Antigens Expressed on Plasmodium falciparum Infected Erythrocytes Using Flow Cytometry. , 2015, Methods in molecular biology.

[30]  S. Meshnick,et al.  Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria. , 2010, The Lancet. Infectious diseases.

[31]  C. Menéndez,et al.  The burden of malaria in pregnancy in malaria-endemic areas. , 2001, The American journal of tropical medicine and hygiene.